IQVIA

658 articles with IQVIA

• IQVIA to Announce Third-Quarter 2019 Results on October 30, 2019

  10/16/2019

  The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.

• IQVIA Launches Orchestrated Patient Engagement

  10/2/2019

  IQVIA OPE is a SaaS patient engagement solution that bridges the gap between life sciences companies and patients

• IQVIA Launches IQVIA Consumer Health to Meet the Growing Business Needs of the Retail Health Sector

  10/1/2019

  IQVIA Consumer Health announces its unique global technology and analytics suite to support the self-care and wellness industry from product concept to consumer use

• IQVIA Collaborates with Cancer Researchers to Advance Use of Real World Evidence

  9/18/2019

  IQVIA™ (NYSE:IQV) is proud to announce its collaboration with Friends of Cancer Research in a cross-industry effort to advance acceptance and drive future uses of real world evidence (RWE).

• IQVIA MedTech Launches Enhanced EQMS including EU MDR Support

  9/17/2019

  The first Enterprise Quality Management Solution in the industry with expanded capabilities for European Union Medical Device Regulation regulations and compliance

• IQVIA Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation

  8/26/2019

  The offer is for approximately 0.51 percent of the common shares outstanding.

• IQVIA to Participate in Baird 2019 Global Healthcare Conference on September 4, 2019

  8/21/2019

  IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Baird 2019 Global Healthcare Conference in New York, NY on Wednesday, September 4, 2019 at 9:40 a.m. ET.

• IQVIA Launches Patient Portal to Transform the Clinical Trial Experience

  8/15/2019

  IQVIA™ (NYSE:IQV) announces its launch of the IQVIA Patient Portal, a global web-based solution built on a leading health cloud platform.

• IQVIA Announces Repurchase of Common Stock

  8/8/2019

  IQVIA expects to fund the Repurchase with cash on hand and borrowings from its revolving credit facility.

• IQVIA Named Real World Evidence Market Leader

  8/5/2019

  IQVIA™ (NYSE:IQV) today announced that a new Life Science Strategy Group (LSSG) report named IQVIA the market leader in real world data and real world evidence services.

• IQVIA’s Cynthia Verst Honored on 2019 PharmaVOICE 100 List

  8/1/2019

  IQVIA™ announced that Cynthia Verst, IQVIA’s president, Design and Delivery Innovation, Research & Development Solutions, has been named to PharmaVOICE magazine’s annual list of the 100 most influential and inspiring individuals within the life sciences industry.

• IQVIA Announces Pricing of Offering of Senior Notes - July 30, 2019

  7/30/2019

  IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., priced an offering of €720,000,000 in aggregate principal amount of senior notes due 2028.

• IQVIA Reports Second-Quarter 2019 Results, Raises Full-Year Revenue and Adjusted Diluted EPS Guidance

  7/24/2019

  IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, reported financial results for the quarter ended June 30, 2019.

• IQVIA Awarded Frost & Sullivan’s Life Sciences Product Leadership Award for Its Advanced Quality Management Technology Solution

  7/23/2019

  IQVIA™ (NYSE:IQV) today announced it has received the Frost & Sullivan’s 2018 Global Enterprise Quality Management Solutions for Life Sciences Product Leadership award.

• IQVIA Named to Forbes 2019 List of America’s Best Employers for Women

  7/22/2019

  IQVIA Holdings Inc. (“IQVIA™”) (NYSE: IQV) has been named to the Forbes 2019 list of America’s Best Employers for Women

• IQVIA to Announce Second-Quarter 2019 Results on July 24, 2019

  7/9/2019

  IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will announce its second-quarter 2019 financial results before the market opens on Wednesday, July 24, 2019.

• Lannett Enters Into Distribution Agreement For Dantrolene Capsules, Commences Product Launch

  6/28/2019

  Lannett Company, Inc. announced that it has entered into a three-year agreement with Elite Pharmaceuticals to be the exclusive U.S. distributor of a Dantrolene Capsules 25 mg, 50 mg and 100 mg.

• IQVIA Introduces Patient Centered Endpoints Solution with Transformative eCOA Technology Platform

  6/25/2019

  Disruptive tech simplifies patient engagement and amplifies patients’ voices to advance outcomes for life science companies

• Chiesi Group Selects IQVIA’s OCE Technology Platform to Develop a Customer Centric Ecosystem across the Organization

  6/17/2019

  Leveraging innovative technology to orchestrate cross functional teamwork and multichannel interactions with external stakeholders

• Clinical Ink’s Jonathan Andrus Invited to Speak at the Duke-Margolis Center for Health Policy Public Meeting

  6/13/2019

  Clinical Ink is pleased to announce that Jonathan Andrus, chief business officer at Clinical Ink, has been invited to be a panelist in a public meeting hosted by the Duke-Margolis Center for Health Policy on July 17, 2019, in Washington, D.C. The workshop, convened under a cooperative agreement with the FDA, will discuss opportunities to improve the implementation of risk-based monitoring (RBM) in clinical investigations.